AveXis Inc (NASDAQ:AVXS) has received a consensus recommendation of “Buy” from the twenty analysts that are presently covering the company, MarketBeat reports. Three research analysts have rated the stock with a sell rating, four have assigned a hold rating and thirteen have issued a buy rating on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $110.56.
A number of research analysts have weighed in on the company. Royal Bank of Canada reaffirmed a “hold” rating and set a $92.00 target price on shares of AveXis in a report on Thursday, November 2nd. Canaccord Genuity assumed coverage on AveXis in a report on Thursday, October 26th. They set a “hold” rating and a $110.00 target price for the company. Zacks Investment Research lowered AveXis from a “buy” rating to a “hold” rating in a report on Monday, October 30th. BidaskClub raised AveXis from a “sell” rating to a “hold” rating in a report on Thursday, December 21st. Finally, Citigroup lifted their target price on AveXis from $100.00 to $116.00 and gave the company a “buy” rating in a report on Monday, October 2nd.
AveXis (AVXS) traded down $2.66 during mid-day trading on Monday, reaching $102.08. The company’s stock had a trading volume of 837,600 shares, compared to its average volume of 502,150. The stock has a market cap of $3,264.15, a price-to-earnings ratio of -18.29 and a beta of 2.46. AveXis has a 1-year low of $50.56 and a 1-year high of $116.15.
In other news, VP Sukumar Nagendran sold 1,780 shares of the business’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $101.26, for a total transaction of $180,242.80. Following the completion of the transaction, the vice president now owns 1,780 shares of the company’s stock, valued at $180,242.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Brian K. Kaspar sold 15,000 shares of the business’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $101.23, for a total value of $1,518,450.00. Following the transaction, the insider now directly owns 1,841,019 shares of the company’s stock, valued at approximately $186,366,353.37. The disclosure for this sale can be found here. Insiders have sold 52,340 shares of company stock valued at $5,318,845 in the last three months. 18.60% of the stock is owned by insiders.
A number of large investors have recently added to or reduced their stakes in the stock. California Public Employees Retirement System bought a new stake in AveXis in the 3rd quarter worth approximately $570,000. Cubist Systematic Strategies LLC lifted its position in AveXis by 688.6% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 1,806 shares of the company’s stock worth $175,000 after buying an additional 1,577 shares during the last quarter. Highbridge Capital Management LLC bought a new stake in AveXis in the 3rd quarter worth approximately $967,000. Perceptive Advisors LLC lifted its position in AveXis by 147.5% in the 3rd quarter. Perceptive Advisors LLC now owns 671,181 shares of the company’s stock worth $64,923,000 after buying an additional 400,000 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its position in AveXis by 52.2% in the 3rd quarter. Janus Henderson Group PLC now owns 1,027,221 shares of the company’s stock worth $99,363,000 after buying an additional 352,456 shares during the last quarter. Institutional investors own 92.88% of the company’s stock.
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.